{"title":"Cisd2单倍体不全:肝细胞癌的驱动力。","authors":"Zhao-Qing Shen, Yi-Long Huang, Ting-Fen Tsai","doi":"10.1080/23723556.2018.1441627","DOIUrl":null,"url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is the major risk factor leading to hepatocellular carcinoma (HCC). <i>Cisd2</i> haploinsufficiency in mice causes NAFLD by disrupting Ca<sup>2+</sup> homeostasis, indicating that CISD2 is a molecular target for the treatment of NAFLD and the prevention of HCC.</p>","PeriodicalId":520710,"journal":{"name":"Molecular & cellular oncology","volume":" ","pages":"e1441627"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23723556.2018.1441627","citationCount":"11","resultStr":"{\"title\":\"<i>Cisd2</i> haploinsufficiency: A driving force for hepatocellular carcinoma.\",\"authors\":\"Zhao-Qing Shen, Yi-Long Huang, Ting-Fen Tsai\",\"doi\":\"10.1080/23723556.2018.1441627\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is the major risk factor leading to hepatocellular carcinoma (HCC). <i>Cisd2</i> haploinsufficiency in mice causes NAFLD by disrupting Ca<sup>2+</sup> homeostasis, indicating that CISD2 is a molecular target for the treatment of NAFLD and the prevention of HCC.</p>\",\"PeriodicalId\":520710,\"journal\":{\"name\":\"Molecular & cellular oncology\",\"volume\":\" \",\"pages\":\"e1441627\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23723556.2018.1441627\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular & cellular oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23723556.2018.1441627\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular & cellular oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723556.2018.1441627","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Cisd2 haploinsufficiency: A driving force for hepatocellular carcinoma.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is the major risk factor leading to hepatocellular carcinoma (HCC). Cisd2 haploinsufficiency in mice causes NAFLD by disrupting Ca2+ homeostasis, indicating that CISD2 is a molecular target for the treatment of NAFLD and the prevention of HCC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
